NCT05967520招募中2 期
A Phase IIa ,Randomized, Double-blind, Placebo-controlled, Dose-exploration Study of JMKX000189 in Treatment of Moderate to Severe Active Systemic Lupus Erythematosus
Jemincare17 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2023年9月21日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 48
- 试验地点
- 17
- 主要终点
- Change in Total Lymphocyte Count From Baseline to Week 12
研究概览
简要总结
The trial will evaluate pharmacodynamics，pharmacokinetics，safety，and efficacy of JMKX000189 versus placebo in participants with moderately to severely active systemic lupus erythematosus (SLE) while receiving standard of care (SOC) treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must have been diagnosed with systemic lupus erythematosus at least 24 weeks prior to screening and must be assessed to meet 2019 EULAR/ACR SLE classification criteria during screening.
- •the subject must meet one of the following at screening: a. ANA titer ≥1:80;b. anti-dsDNA antibody positive; c. Anti-Smith antibody positive.
- •At least one of the following SLE background standard therapies (including no more than one immunosuppressant) was required for 12 weeks prior to randomization, and the dose must remain stable at least 30 days until randomization and throughout study participation.
排除标准
- •Active lupus nephritis (defined as urinary protein >1g/24 h or urinary total protein/creatinine ratio (UPCR) >1 mg/mg (113 mg/mmol) within 8 weeks prior to screening or at randomization).
- •Active lupus of the central nervous system (CNS) (including epilepsy, psychosis, organic encephalopathy syndrome, cerebrovascular accident, encephalitis, or CNS vasculitis) within 60 days prior to randomization.
- •Myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, grade III/IV heart failure, or untreated severe sleep apnea occurred ≤6 months before screening.
- •Previous or current atrioventricular block of degree Ⅱ or Ⅲ, sick sinus syndrome, symptomatic bradycardia, atrial flutter or atrial fibrillation, ventricular arrhythmia or syncope associated with heart disease, or other arrhythmia deemed clinically significant and requiring intervention or treatment.
- •A history of severe respiratory disease or interstitial pneumonia or pulmonary fibrosis，which were found by the medical history or lung function test or chest CT examination conducted during screening or within 3 months prior to screening;Or abnormal pulmonary function of medical significance: 1 second forced expiratory volume (FEV1) or forced vital capacity (FVC)<70% of the expected value, or FEV1 /FVC < 0.
- •Patients with significant abnormalities in liver, renal function and blood routine during screening, including glutamate aminotransferase (ALT) or aspartate aminotransferase (AST) exceeding 2 times the upper limit of normal value;Serum creatinine greater than 1.5 times the upper limit of normal;Hemoglobin <90g/L;White blood cell count <2.5×109/L, platelet count (PLT) <75×109/L;Lymphocyte count <0.8×109/L;Abnormal results of other laboratory tests may affect the completion of the test or interfere with the test results according to the investigator.
- •Use of cyclosporine, tacrolimus, pimelimus, and sirolimus within 1 month prior to randomization.
- •Use of thalidomide or lenalidomide within 2 months prior to randomization.
- •Rituximab, telitacicept, or leflunomide were used in the 6 months prior to randomization.
- •Use of Belliumab within 3 months prior to randomization.
- •Intravenous treatment with cyclophosphamide was received within 6 months prior to randomization or oral treatment with cyclophosphamide within 30 days prior to initial administration.
- •History of type 1 diabetes mellitus, or uncontrolled Type 2 diabetes mellitus with HbA1c> 8%, or diabetic subjects with organ involvement (e.g. retinopathy or kidney disease).
研究组 & 干预措施
Placebo
Placebo Comparator
Randomized 16 patients will be received Placebo in oral continuously from Week 0 to Week 12 in addition to SOC.
干预措施: Placebo (Drug)
JMKX000189 - higher dose
Experimental
Randomized 16 patients will be received JMKX000189 at a higher dose in oral continuously from Week 0 to Week 12 in addition to SOC.
干预措施: JMKX000189 (Drug)
JMKX000189 - lower dose
Experimental
Randomized 16 patients will be received JMKX000189 at a lower dose in oral continuously from Week 0 to Week 12 in addition to SOC.
干预措施: JMKX000189 (Drug)
结局指标
主要结局
Change in Total Lymphocyte Count From Baseline to Week 12
时间窗: Baseline,Week 12
次要结局
- Change from baseline to Week 4,8,12 and 16 in the modified SLEDAI (mSLEDAI) score(Baseline, Week 4, 8,12, and 16)
- Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index-4 (SRI-4) Response at Week 4,8,12 and 16(Baseline, Week 4, 8,12, and 16)
- Percentage of Participants Achieving No worsening in Physician Global Assessment (PGA) of Disease Activity at Week 4,8,12 and 16, No worsening defined as an increase of PGA < 0.3 Points from baseline(Baseline, Week 4, 8,12, and 16)
研究者
研究点 (17)
Loading locations...
相似试验
已完成
2 期
MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)Paranoid SchizophreniaNCT00506077Merck Sharp & Dohme LLC55
招募中
2 期
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01NPDR - Non Proliferative Diabetic RetinopathyDiabetic RetinopathyNCT06770933Vantage Biosciences Ltd100
已完成
2 期
Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR MutationCystic FibrosisNCT01225211Vertex Pharmaceuticals Incorporated312
招募中
2 期
A Study of ORX750 in Subjects with Narcolepsy and Idiopathic Hypersomnia2024-518929-15-00Centessa Pharmaceuticals UK Limited96
已完成
2 期
Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes MellitusType 1 Diabetes MellitusNCT01742208Lexicon Pharmaceuticals36